Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

ABSTRACT:

SUBMITTER: Regula JT 

PROVIDER: S-EPMC6505574 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature